市场调查报告书
商品编码
1396595
避孕药具市场 - 按产品(药物、器材)、按年龄层(15-44 岁、44 岁以上)、按配销通路(医院药房、零售药房、线上管道),- 全球预测,2023-2032 年Contraceptives Market - By Product (Drugs, Devices), By Age Group (15-44 Years, above 44 Years), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channels), - Global Forecast, 2023-2032 |
由于人们对计划生育的认识不断增强以及人口控制的重要性,预计从 2023 年到 2032 年,避孕药具市场规模将以 6.3% 的CAGR扩大。对妇女健康、教育和赋权的日益关注导致对避孕药具的需求增加。避孕技术的不断进步正在为开发更方便、更有效的消费方法铺平道路。例如,2023年7月,美国FDA批准Opil(炔诺孕酮)片剂用于非处方用途,这标誌着美国首次授权每日口服避孕药无需处方即可在非处方药中使用。
此外,性传染感染(STI)盛行率的上升鼓励了屏障方法的使用。为了追求职业而延迟生育和计划生育的趋势不断上升,也推动了避孕药具的采用。政府为促进生殖健康而采取的措施和宣传活动的大量涌入也对市场成长产生了积极影响。
避孕药具市场按产品、年龄层、配销通路和地区划分。
根据产品,预计 2023 年至 2032 年药品领域的产业规模复合CAGR为 3.9%。这一增长可归因于荷尔蒙和非荷尔蒙避孕药研发活动的增加。人们对计划生育的认识不断提高、製药技术的进步以及妇女健康措施的不断扩大将推动产品需求。
预计 2023 年至 2032 年,44 岁以上年龄层的避孕药具市占率将以 5.6% 的CAGR成长。这可以归因于延迟生育的趋势上升、对计划生育意识的增强以及老年人对有效节育方法的更大渴望。针对该年龄层特定需求的避孕选择的不断进步也将促进该细分市场的成长。
从地区来看,由于计划生育意识不断增强以及政府促进生殖健康的倡议不断涌现,亚太地区避孕药具市场规模预计从 2023 年到 2032 年将以 7.9% 的CAGR增长。此外,文化转变、城市化以及对妇女教育和赋权的日益关注将推动整个地区对避孕药具的需求。
Contraceptives market size is projected to expand at 6.3% CAGR from 2023 to 2032, on account of the increasing awareness about family planning and the importance of population control. The growing focus on women health, education, and empowerment is contributing to higher demand for contraceptives. The rising advancement in contraceptive technologies is making way for the development of more convenient and effective methods for consumption. For instance, in July 2023, the U.S. FDA granted approval for Opill (norgestrel) tablets for nonprescription use, marking the first authorization of a daily oral contraceptive for over-the-counter use in the U.S. without a prescription.
Moreover, the rising prevalence of sexually transmitted infections (STIs) is encouraging the use of barrier methods. The rising trend of delayed parenthood and family planning for career pursuits is also driving the adoption of contraceptives. The influx of government initiatives and awareness campaigns for promoting reproductive health is also positively affecting the market growth.
The contraceptives market is segregated into product, age group, distribution channel, and region.
Based on product, the industry size from the drugs segment is projected to depict 3.9% CAGR from 2023 to 2032. The growth can be ascribed to the increasing R&D activities in hormonal and non-hormonal contraceptive drugs. The rising awareness about family planning, the higher advancements in pharmaceutical technologies, and the expanding initiatives for women health will fuel the product demand.
Contraceptives market share from the above 44 years age group segment is projected to rise at 5.6% CAGR during 2023-2032. This can be attributed to the rising trend of delayed parenthood, increased awareness of family planning, and the greater desire for effective birth control methods among older individuals. The growing advancements in contraceptive options tailored to the specific needs of this age group will also boost the segment growth.
Regionally, the Asia Pacific contraceptives market size is projected to grow at 7.9% CAGR from 2023 to 2032 due to the increasing awareness of family planning and the influx of government initiatives for promoting reproductive health. Additionally, cultural shifts, urbanization, and the growing focus on women education and empowerment will fuel the demand for contraceptives across the region.